Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Therapy

Study Background and Research Question

Melanoma is recognized as the most aggressive form of skin cancer, characterized by high metastatic potential and resistance to conventional therapies such as immune checkpoint inhibitors (ICIs). While ICIs like anti-PD-1 and anti-CTLA-4 have transformed the treatment landscape, less than half of patients experience lasting benefit due to tumor resistance mechanisms. A major contributor to this resistance is the loss or mutation of the phosphatase and tensin homolog (PTEN) tumor suppressor gene. PTEN regulates cell proliferation and survival through inhibition of the PI3K/Akt signaling pathway and is frequently inactivated in melanoma, leading to unchecked tumor growth and impaired immune responses. Restoring PTEN expression represents a compelling strategy to both suppress tumor progression and re-engage antitumor immunity. However, safe and efficient delivery of functional PTEN to tumor cells remains a significant challenge, particularly for topical, non-invasive cancer immunotherapies.

Key Innovation from the Reference Study

The reference study introduces a novel platform for transdermal cancer immunotherapy using hyaluronate-conjugated lipid nanoparticles (HA-LNPs) to deliver PTEN mRNA directly through the skin (Kim et al., 2026). This approach leverages the biocompatibility and skin-penetrating properties of hyaluronate (HA), a glycosaminoglycan that targets CD44-expressing cells commonly present in skin and melanoma. A key innovation is the direct integration of HA-dimyristoyl glycerol (HA-DMG) during nanoparticle self-assembly, eliminating the need for polyethylene glycol (PEG) modifications, which have been associated with immunogenicity and adverse reactions. The resulting HA-LNPs enable stable encapsulation and delivery of large mRNA payloads, while enhancing targeting specificity and minimizing off-target effects. This platform facilitates localized, non-invasive administration, potentially broadening the clinical utility of mRNA therapeutics for cutaneous malignancies.

Methods and Experimental Design Insights

The experimental workflow capitalized on the self-assembly of HA-LNPs using HA-DMG, which stably incorporates into the lipid bilayer and displays HA moieties on the nanoparticle surface. This design supports both colloidal stability and biological targeting. PTEN mRNA, chemically modified for enhanced stability and translation, was encapsulated within these nanoparticles. The researchers optimized the formulation to maximize mRNA payload while preserving particle uniformity and biocompatibility. In vitro studies involved treating CD44-positive melanoma cell lines with PTEN mRNA-loaded HA-LNPs to assess restoration of PTEN expression, cell viability, and induction of immunogenic cell death (ICD). For in vivo evaluation, the HA-LNPs were topically applied to melanoma-bearing mouse models. Tumor penetration, PTEN expression, antitumor immunity, and systemic toxicity were systematically assessed. The study design allowed for direct comparison between HA-LNPs and conventional PEGylated nanoparticles, as well as untreated and negative control groups.

Protocol Parameters

• HA-LNP Preparation: Incorporate HA-DMG during lipid nanoparticle self-assembly to ensure stable HA surface presentation and avoid PEG-related immunogenicity.
• mRNA Encapsulation: Use chemically modified PTEN mRNA for enhanced stability; encapsulate at optimal ratios for maximal payload and particle uniformity.
• In Vitro Treatment: Apply PTEN mRNA@HA-LNPs to CD44-positive melanoma cells; assess PTEN restoration, viability, and markers of immunogenic cell death.
• In Vivo Application: Topically administer HA-LNPs to melanoma-bearing mice; monitor tumor penetration, immune activation, and toxicity.
• Assessment of Outcomes: Quantify PTEN expression, tumor growth inhibition, immune cell infiltration, and safety metrics post-treatment.

Core Findings and Why They Matter

The study demonstrated that HA-LNPs efficiently encapsulate and deliver PTEN mRNA across the skin barrier, selectively targeting CD44-expressing melanoma cells. In vitro, treatment with PTEN mRNA@HA-LNPs restored functional PTEN protein, induced immunogenic cell death, and reduced melanoma cell viability. In vivo, topically applied HA-LNPs achieved deep tumor penetration and resulted in significant tumor growth inhibition in mouse models, accompanied by increased immune cell infiltration and minimal systemic toxicity. Compared to conventional PEGylated nanoparticles, HA-LNPs showed superior skin penetration, biocompatibility, and targeting specificity (Kim et al., 2026). These findings highlight the promise of HA-LNPs as a clinically translatable platform for localized mRNA-based cancer immunotherapy, overcoming key limitations of prior gene delivery systems such as poor cytosolic delivery, immunogenicity, and risk of genomic integration.

Comparison with Existing Internal Articles

Several recent articles reinforce the utility of PTEN mRNA restoration strategies in cancer research. For instance, one summary emphasizes the potential of HA-LNPs for efficient, non-invasive PTEN mRNA delivery and immune reactivation in melanoma. Another internal overview (see here) details the clinical relevance and biocompatibility advantages of this approach. Meanwhile, protocol-driven articles focusing on laboratory workflows, such as those featuring the EZ Cap™ Human PTEN mRNA reagent (relevant guide), highlight the importance of mRNA quality—including Cap 1 structures and poly(A) tail modifications—for robust, reproducible PTEN expression in both cancer research and gene therapy settings. Collectively, these resources underscore the shift toward mRNA-based, immune-evasive, and targeted delivery modalities as the field advances.

Limitations and Transferability

While the HA-LNP system demonstrates robust efficacy and specificity in preclinical models, several limitations remain. Most notably, translation to human patients will require careful assessment of long-term safety, large-scale nanoparticle production, and reproducibility across diverse skin types and tumor microenvironments. The current work is primarily focused on melanoma, where the abundance of CD44-expressing cells and the accessibility of skin tumors facilitate localized delivery. Broader application to other cancer types or systemic disease may require further optimization of targeting ligands, dosing regimens, and nanoparticle composition. Additionally, while chemically modified mRNA reduces innate immune activation, comprehensive immunogenicity profiles will be essential in future clinical studies.

Research Support Resources

For researchers aiming to replicate or extend these findings in cancer research or gene therapy studies, high-quality mRNA reagents are essential. Products such as EZ Cap™ Human PTEN mRNA (SKU R1025) offer a reliable source of in vitro transcribed, Cap 1-modified PTEN mRNA with a poly(A) tail for enhanced stability and translational efficiency, as recommended in current nanoparticle workflows. This reagent supports advanced mRNA transfection and expression protocols and is compatible with HA-LNP or other delivery formats. For best results, handle according to the product guidelines to minimize degradation and ensure reproducible outcomes. APExBIO provides rigorous quality control, including capping efficiency and sterility, making this resource valuable for both exploratory and translational cancer immunotherapy research.